Background: Galectin-3 is a member of a closely related lectin family, which is detected in several vertebrate epithelial and myeloid cell types. This beta-galactoside-binding soluble protein plays an important role in multiple biological processes. Depending on its location, type of injury or site of damage, the effects by galectin-3 can be various and sometimes contrasting. Summary: In this review, we discuss the general characteristics and functions of galectin-3. More specifically, we focus on the role of galectin-3 in the onset and development of diabetic and non-diabetic nephropathies. Finally, the therapeutic potential of anti-galectin-3 inhibitors is discussed. Key Messages: Due to its multifunctional character, galectin-3 plays a pivotal role in interstitial fibrosis and progression of chronic kidney disease. Inhibition of galectin-3 may be a promising therapeutic strategy to prevent end-stage renal disease.

Keywords:
Galectin-3, Kidney disease, Lectin, Renal fibrosis
1.
Vijayakumar S, Peng H, Schwartz GJ: Galectin-3 mediates oligomerization of secreted hensin using its carbohydrate-recognition domain. Am J Physiol Renal Physiol 2013;305:F90-F99.
2.
Poland PA, Rondanino C, Kinlough CL, et al: Identification and characterization of endogenous galectins expressed in Madin Darby canine kidney cells. J Biol Chem 2011;286:6780-6790.
3.
Friedrichs J, Manninen A, Muller DJ, Helenius J: Galectin-3 regulates integrin alpha2beta1-mediated adhesion to collagen-I and -IV. J Biol Chem 2008;283:32264-32272.
4.
Fernandes Bertocchi AP, Campanhole G, Wang PH, et al: A role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transpl Int 2008;21:999-1007.
5.
Nio J, Takahashi-Iwanaga H, Morimatsu M, Kon Y, Iwanaga T: Immunohistochemical and in situ hybridization analysis of galectin-3, a beta-galactoside binding lectin, in the urinary system of adult mice. Histochem Cell Biol 2006;126:45-56.
6.
Bao Q, Hughes RC: Galectin-3 expression and effects on cyst enlargement and tubulogenesis in kidney epithelial MDCK cells cultured in three-dimensional matrices in vitro. J Cell Sci 1995;108(pt 8):2791-2800.
7.
Nieminen J, Kuno A, Hirabayashi J, Sato S: Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J Biol Chem 2007;282:1374-1383.
8.
Lepur A, Salomonsson E, Nilsson UJ, Leffler H: Ligand induced galectin-3 protein self-association. J Biol Chem 2012;287:21751-21756.
9.
von Mach T, Carlsson MC, Straube T, Nilsson U, Leffler H, Jacob R: Ligand binding and complex formation of galectin-3 is modulated by pH variations. Biochem J 2014;457:107-115.
10.
Schwaderer AL, Vijayakumar S, Al-Awqati Q, Schwartz GJ: Galectin-3 expression is induced in renal beta-intercalated cells during metabolic acidosis. Am J Physiol Renal Physiol 2006;290:F148-F158.
11.
Winyard PJ, Bao Q, Hughes RC, Woolf AS: Epithelial galectin-3 during human nephrogenesis and childhood cystic diseases. J Am Soc Nephrol 1997;8:1647-1657.
12.
Liu FT, Patterson RJ, Wang JL: Intracellular functions of galectins. Biochim Biophys Acta 2002;1572:263-273.
13.
Van den Brule FA, Fernandez PL, Buicu C, et al: Differential expression of galectin-1 and galectin-3 during first trimester human embryogenesis. Dev Dyn 1997;209:399-405.
14.
Colnot C, Fowlis D, Ripoche MA, Bouchaert I, Poirier F: Embryonic implantation in galectin 1/galectin 3 double mutant mice. Dev Dyn 1998;211:306-313.
15.
Vasta GR: Galectins as pattern recognition receptors: structure, function, and evolution. Adv Exp Med Biol 2012;946:21-36.
16.
Kuklinski S, Probstmeier R: Homophilic binding properties of galectin-3: involvement of the carbohydrate recognition domain. J Neurochem 1998;70:814-823.
17.
Straube T, von Mach T, Hönig E, Greb C, Schneider D, Jacob R: pH-dependent recycling of galectin-3 at the apical membrane of epithelial cells. Traffic 2013;14:1014-1027.
18.
Christenson RH, Duh SH, Wu AH, et al: Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin Biochem 2010;43:683-690.
19.
Gaze DC, Prante C, Dreier J, et al: Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments. Clin Chem Lab Med 2014;52:919-926.
20.
Gruson D, Mancini M, Ahn SA, Rousseau MF: Galectin-3 testing: validity of a novel automated assay in heart failure patients with reduced ejection fraction. Clin Chim Acta 2014;429:189-193.
21.
Lameire N, Van Biesen W, Vanholder R: Acute renal failure. Lancet 2005;365:417-430.
22.
Lameire N: The definitions and staging systems of acute kidney injury and their limitations in practice. Arab J Nephrol Transplant 2013;6:145-152.
23.
Nishiyama J, Kobayashi S, Ishida A, et al: Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol 2000;157:815-823.
24.
Tang WH, Shrestha K, Shao Z, et al: Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011;108:385-390.
25.
O'Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS: Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol 2013;24:1470-1477.
26.
Iacoviello M, Aspromonte N, Leone M, et al: Galectin-3 serum levels are independently associated with microalbuminuria in chronic heart failure outpatients. Res Cardiovasc Med 2015;5:e28952.
27.
Bansal N, Katz R, Seliger S, et al: Galectin-3 and soluble ST2 and kidney function decline in older adults: the Cardiovascular Health Study (CHS). Am J Kidney Dis 2016;pii:S0272-6386(16)00013-5.
28.
Meijers WC, van der Velde AR, Ruifrok WP, et al: Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis. J Am Heart Assoc 2014;3:e000962.
29.
Savic J, Zeljkovic A, Bogavac-Stanojevic N, et al: Association of small, dense low-density lipoprotein cholesterol and galectin-3 in patients with chronic kidney disease. Scand J Clin Lab Invest 2014;74:637-643.
30.
Hogas S, Schiller A, Voroneanu L, et al: Predictive value for galectin 3 and cardiotrophin 1 in hemodialysis patients. Angiology 2016;pii:0003319715623397.
31.
Vlassara H: Protein glycation in the kidney: role in diabetes and aging. Kidney Int 1996;49:1795-1804.
32.
Pugliese G, Iacobini C, Pesce CM, Menini S: Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology 2015;25:136-150.
33.
Vlassara H, Li YM, Imani F, et al: Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995;1:634-646.
34.
Pugliese G, Pricci F, Iacobini C, et al: Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J 2001;15:2471-2479.
35.
Iacobini C, Menini S, Oddi G, et al: Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 2004;18:1773-1775.
36.
Kikuchi Y, Kobayashi S, Hemmi N, et al: Galectin-3-positive cell infiltration in human diabetic nephropathy. Nephrol Dial Transplant 2004;19:602-607.
37.
Drechsler C, Delgado G, Wanner C, et al: Galectin-3, renal function, and clinical outcomes: results from the LURIC and 4D studies. J Am Soc Nephrol 2015;26:2213-2221.
38.
Jeon SB, Yoon HJ, Chang CY, Koh HS, Jeon SH, Park EJ: Galectin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway. J Immunol 2010;185:7037-7046.
39.
Watson AM, Li J, Samijono D, et al: Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice. Atherosclerosis 2014;235:444-448.
40.
Cucak H, Nielsen Fink L, Højgaard Pedersen M, Rosendahl A: Enalapril treatment increases T cell number and promotes polarization towards M1-like macrophages locally in diabetic nephropathy. Int Immunopharmacol 2015;25:30-42.
41.
de Boer RA, van Veldhuisen DJ, Gansevoort RT, et al: The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012;272:55-64.
42.
Gasparitsch M, Arndt AK, Pawlitschek F, et al: RAGE-mediated interstitial fibrosis in neonatal obstructive nephropathy is independent of NF-κB activation. Kidney Int 2013;84:911-919.
43.
Henderson NC, Mackinnon AC, Farnworth SL, et al: Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008;172:288-298.
44.
Dang Z, MacKinnon A, Marson LP, Sethi T: Tubular atrophy and interstitial fibrosis after renal transplantation is dependent on galectin-3. Transplantation 2012;93:477-484.
45.
Okamura DM, Pasichnyk K, Lopez-Guisa JM, et al: Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol 2011;300:F245-F253.
46.
Li LC, Li J, Gao J: Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther 2014;351:336-343.
47.
Vansthertem D, Cludts S, Nonclercq D, et al: Immunohistochemical localization of galectins-1 and -3 and monitoring of tissue galectin-binding sites during tubular regeneration after renal ischemia reperfusion in the rat. Histol Histopathol 2010;25:1417-1429.
48.
Tumlin JA, Costanzo MR, Chawla LS, et al: Cardiorenal syndrome type 4: insights on clinical presentation and pathophysiology from the eleventh consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol 2013;182:158-173.
49.
Hundae A, McCullough PA: Cardiac and renal fibrosis in chronic cardiorenal syndromes. Nephron Clin Pract 2014;127:106-112.
50.
Sharma UC, Pokharel S, van Brakel TJ, et al: Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110:3121-3128.
51.
Lin YH, Lin LY, Wu YW, et al: The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009;409:96-99.
52.
Gopal DM, Kommineni M, Ayalon N, et al: Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc 2012;1:e000760.
53.
Winyard PJ, Bao Q, Hughes RC, Woolf AS: Epithelial galectin-3 during human nephrogenesis and childhood cystic diseases. J Am Soc Nephrol 1997;8:1647-1657.
54.
Bullock SL, Johnson TM, Bao Q, Hughes RC, Winyard PJ, Woolf AS: Galectin-3 modulates ureteric bud branching in organ culture of the developing mouse kidney. J Am Soc Nephrol 2001;12:515-523.
55.
Hikita C, Vijayakumar S, Takito J, Erdjument-Bromage H, Tempst P, Al-Awqati Q: Induction of terminal differentiation in epithelial cells requires polymerization of hensin by galectin 3. J Cell Biol 2000;151:1235-1246.
56.
Guay-Woodford LM, Desmond RA: Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics 2003;111(5 pt 1):1072-1080.
57.
Bao Q, Hughes RC: Galectin-3 and polarized growth within collagen gels of wild-type and ricin-resistant MDCK renal epithelial cells. Glycobiology 1999;9:489-495.
58.
Chiu MG, Johnson TM, Woolf AS, et al: Galectin-3 associates with the primary cilium and modulates cyst growth in congenital polycystic kidney disease. Am J Pathol 2006;169:1925-1938.
59.
Huang CS, Tang SJ, Chung LY, et al: Galectin-1 upregulates CXCR4 to promote tumor progression and poor outcome in kidney cancer. J Am Soc Nephrol 2014;25:1486-1495.
60.
Kaneko N, Gotoh A, Okamura N, et al: Potential tumor markers of renal cell carcinoma: α-enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection. Int J Urol 2013;20:530-535.
61.
Straube T, Elli AF, Greb C, et al: Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma. J Exp Clin Cancer Res 2011;30:89.
62.
Sakaki M, Fukumori T, Fukawa T, et al: Clinical significance of galectin-3 in clear cell renal cell carcinoma. J Med Invest 2010;57:152-157.
63.
von Klot CA, Kramer MW, Peters I, et al: Galectin-1 and galectin-3 mRNA expression in renal cell carcinoma. BMC Clin Pathol 2014;14:15.
64.
Dancer JY, Truong LD, Zhai Q, Shen SS: Expression of galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker. Arch Pathol Lab Med 2010;134:90-94.
65.
Bing Z, Lal P, Lu S, Ziober A, Tomaszewski JE: Role of carbonic anhydrase IX, α-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: a tissue microarray immunohistochemical study. Ann Diagn Pathol 2013;17:58-62.
66.
Merseburger AS, Kramer MW, Hennenlotter J, et al: Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol 2008;26:637-642.
67.
Takenaka Y, Fukumori T, Raz A: Galectin-3 and metastasis. Glycoconj J 2004;19:543-549.
68.
Xu Y, Gu X, Gong M, Guo G, Han K, An R: Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment. Cancer Biol Ther 2013;14:897-906.
69.
Ostalska-Nowicka D, Nowicki M, Kondraciuk B, Partyka M, Samulak D, Witt M: Expression of galectin-3 in nephrotic syndrome glomerulopaties in children. Folia Histochem Cytobiol 2009;47:315-322.
70.
Kang EH, Moon KC, Lee EY, et al: Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus 2009;18:22-28.
71.
Sasaki S, Bao Q, Hughes RC: Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J Pathol 1999;187:481-489.
72.
Ponticelli C, Villa M, Cesana B, Montagnino G, Tarantino A: Risk factors for late kidney allograft failure. Kidney Int 2002;62:1848-1854.
73.
Tan R, Liu X, Wang J, et al: Alternations of galectin levels after renal transplantation. Clin Biochem 2014;47:83-88.
74.
Yilmaz H, Inan O, Darcin T, Bilgic MA, Akcay A: Serum galectin-3 levels were associated with proteinuria in patients with familial Mediterranean fever. Clin Exp Nephrol 2015;19:436-442.
75.
Drenth JP, van der Meer JW: Hereditary periodic fever. N Engl J Med 2001;345:1748-1757.
76.
Al-Salam S, Conca W: Novel protagonists in autoinflammatory arthritis of familial Mediterranean fever. Pediatrics 2011;128:e464-e470.
77.
Artini M, Natoli C, Tinari N, et al: Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996;25:212-217.
78.
Longo G, Natoli C, Rafanelli D, et al: Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. Br J Haematol 1993;85:207-209.
79.
Lin YH, Lin LY, Wu YW, et al: The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009;409:96-99.
80.
Hepojoki J, Strandin T, Hetzel U, et al: Acute hantavirus infection induces galectin-3-binding protein. J Gen Virol 2014;95(pt 11):2356-2364.
81.
Altman E, Harrison BA, Latta RK, Lee KK, Kelly JF, Thibault P: Galectin-3-mediated adherence of Proteus mirabilis to Madin-Darby canine kidney cells. Biochem Cell Biol 2001;79:783-788.
82.
Hart PD, Bakris GL: Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother 2010;11:2675-2686.
83.
Frenay AR, Yu L, van der Velde AR, Vreeswijk-Baudoin I, et al: Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. Am J Physiol Renal Physiol 2015;308:F500-F509.
84.
Traber PG, Zomer E: Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One 2013;8:e83481.
85.
Nangia-Makker P, Hogan V, Honjo Y, et al: Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 2002;94:1854-1862.
86.
Inohara H, Raz A: Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions. Glycoconj J 1994;11:527-532.
87.
Ridley BL, O'Neill MA, Mohnen D: Pectins: structure, biosynthesis, and oligogalacturonide-related signaling. Phytochemistry 2001;57:929-967.
88.
Gunning AP, Bongaerts RJ, Morris VJ: Recognition of galactan components of pectin by galectin-3. FASEB J 2009;23:415-424.
89.
Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA: Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS One 2011;6:e18683.
90.
Kahsai AW, Cui J, Kaniskan HU, Garner PP, Fenteany G: Analogs of tetrahydroisoquinoline natural products that inhibit cell migration and target galectin-3 outside of its carbohydrate-binding site. J Biol Chem 2008;283:24534-24545.
91.
Calvier L, Martinez-Martinez E, Miana M, et al: The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail 2015;3:59-67.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.